Industries > Pharma > Antibiotics Market Report to 2031
Antibiotics Market Report to 2031
By Type, The Market Is Categorized As Type (Cephalosporins, Macrolides, Tetracycline, Penicillin, Fluoroquinolones, Aminoglycosides), By Mechanism (Cell Wall Synthesis, Protein Synthesis Inhibitors, DNA Synthesis Inhibitors, RNA Synthesis Inhibitors, Mycolic Acid Synthesis Inhibitors, Folic Acid Synthesis Inhibitors).
Global Antibiotics Market– our new study reveals trends, R&D progress, and predicted revenues
Where is the Global Antibiotics market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2031, assessing data, trends, opportunities, and business prospects there.
Discover how to stay ahead
Our Antibiotics report provides tables and charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Antibiotics Market. See how to exploit the opportunities.
Forecasts to 2031 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints, and challenges), product profiles and commercial developments.
Antibiotics Market by Type
• Cephalosporins
• Macrolides
• Tetracycline
• Penicillin
• Fluoroquinolones
• Aminoglycosides
Antibiotics Market by Mechanism
• Cell Wall Synthesis
• Protein Synthesis Inhibitors
• DNA Synthesis Inhibitors
• RNA synthesis Inhibitors
• Mycolic Acid synthesis inhibitors
• Folic Acid synthesis inhibitors
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 20 leading national markets:
• North America
o U.S.
o Canada
• Europe
o Germany
o France
o United Kingdom
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o Japan
o Rest of Asia Pacific
• Latin America
o Rest of Latin America
• Middle East and Africa
o Rest of Middle East and Africa
The report also includes profiles and for some of the leading companies in the Global Antibiotics Market, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
Overall world revenue for Global Antibiotics Market with forecasts for by type and mechanism each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Global Antibiotics Market report helps you
In summary, our 250+ page report provides you with the following knowledge:
• Revenue forecasts to 2031 for Global Antibiotics Market, with forecasts by type, and by mechanism, each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2031 for 5 regional and 20 key national markets – See forecasts for the Antibiotics market in North America, Europe, Asia-Pacific and Rest of the World. Also forecasted is the market in the US, Canada, Brazil, Germany, France, UK, Italy, Spain, China, India, Japan, Rest of Asia Pacific, Latin America and Middle East and Africa among other prominent economies.
• Prospects for established firms and those seeking to enter the market– including company profiles for Antibiotics of the major companies involved in the Antibiotics Market. Some of the company’s profiled in this report include-
• Pfizer Inc.
• Thermo Fisher Scientific Inc.
• Astellas Pharma, Inc
• F. Hoffmann-La Roche AG
• Novartis AG
• Bristol-Myers Squibb Co.
• Bayer HealthCare AG
• Merck KGaA,
• Abbott Laboratories
• Takeda Pharmaceutical Company Ltd.
• Daiichi Sankyo Company, Ltd.
• GlaxoSmithKline Plc
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
With Information found nowhere else
our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions.
Visiongain’s study is for everybody needing commercial analyses for the global Antibiotics Market and leading companies. You will find data, trends, and predictions.
Get our report today Global Antibiotics Market Forecast 2021-2031: By Type, The Market Is Categorized As Type (Cephalosporins, Macrolides, Tetracycline, Penicillin, Fluoroquinolones, Aminoglycosides), By Mechanism (Cell Wall Synthesis, Protein Synthesis Inhibitors, DNA Synthesis Inhibitors, RNA Synthesis Inhibitors, Mycolic Acid Synthesis Inhibitors, Folic Acid Synthesis Inhibitors).
1. Report Overview
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered by This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Antibiotics Market
2.1. Antibiotics Market Definition
2.2. By Type Submarkets Definitions
2.3. By Mechanism Submarkets Definitions
3. Antibiotics Market Overview
3.1. Global Antibiotics Market Size and Forecast by Region
3.2. Global Antibiotics Market Share by Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Development in Clinical Trials
3.3.1.2. Rising Demand for Antibiotics to Treat Children with Potentially Fatal Sepsis and Pneumonia.
3.3.1.3. Increasing Prevalence of Infectious Diseases
3.3.1.4. Growing Disposable Income
3.3.2. Market Restraints/Challenges
3.3.2.1. Antibiotic Resistance is Major Threat.
3.3.2.2. Development of Antibiotic That are Active Against Antibiotic Resistance.
3.3.3. Opportunities
3.3.3.1. Rising Investment in R&D.
3.3.3.2. Increasing Use of Antibiotics in Veterinary to Prevent Diseases.
3.3.3.3. Growing Need to Prevent Infection in Surgical Patients, Cancer Patients and Patients with Compromised Immune Systems.
3.3.4. Porter’s Five Forces Analysis
3.3.4.1. Competitive Rivalry
3.3.4.2. Supplier Power
3.3.4.3. Buyer Power
3.3.4.4. Threat of Substitution
3.3.4.5. Threat of New Entry
4. Global Antibiotics Market Analysis and Forecast 2021-2031, By Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.2. Cephalosporins
4.2.1.1. Used to Treat Serious Infections, Such as Septicaemia and Meningitis
4.3. Macrolides
4.3.1.1. Used to Treat Penicillin-Resistant Strains of Bacteria.
4.4. Tetracycline
4.4.1.1. Commonly Treat Moderate to Severe Acne and Rosacea.
4.5. Penicillin
4.5.1.1. Broadly Used to Treat Infections, Such as Skin, Ear, Respiratory and Dental Infections.
4.6. Fluoroquinolones
4.6.1.1. Increasing use of Ciprofloxacin, Levofloxacin, to Treat Pneumonia, Sinus, Joint, Urinary Infections, among others.
4.7. Aminoglycosides
4.7.1.1. Used in Hospital to Treat Serious Infections Such as Septicaemia.
5. Global Antibiotics Market Analysis and Forecast, 2021-2031 by Mechanism (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Cell Wall Synthesis
5.1.1.1. Penicillin and Cephalosporins are Major Antibiotics That Inhibit Bacterial Cell Wall Synthesis.
5.1.2. Protein Synthesis Inhibitors
5.1.2.1. Act at the Ribosome Level.
5.1.3. DNA Synthesis Inhibitors
5.1.3.1. Fluoroquinolone Blocks DNA Replication Via Inhibition of DNA Gyrase
5.1.4. RNA Synthesis Inhibitors
5.1.4.1. Rifampin is Effective Against Intracellular Phagocytized Staphylococcus Aureus in Macrophages
5.1.5. Mycolic Acid Synthesis Inhibitors
5.1.5.1. Isoniazid, Mycolic Acid Synthesis Inhibitor.
5.1.6. Folic Acid Synthesis Inhibitors
5.1.6.1. Sulfonamides and Trimethoprim Sequential Blockage of Folic Acid Synthesis.
6. North America Antibiotics Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.2. North America Antibiotics Market Size and Forecast by Type
6.2.1. Penicillin Submarket Expected to Grow at Significant Rate
6.3. North America Antibiotics Market Size and Forecast by Mechanism
6.3.1. Cell Wall Synthesis Industry Submarket to Grow at Significant Rate
6.4. U.S. Antibiotics Market
6.4.1. World Antimicrobial Awareness Week (WAAW) Focuses to Increase Awareness of Antibiotic Resistance
6.5. Canada Antibiotics Market
6.5.1. Increasing Antibiotic Prescription for Respiratory and Urinary Tract Infections (UTI).
7. Europe Antibiotics Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.2. Europe Antibiotics Market Size and Forecast by Type
7.2.1. Penicillin Submarket Expected to Grow at Significant Rate
7.3. Europe Antibiotics Market Size and Forecast by Mechanism
7.3.1. Cell Wall Synthesis Submarket to Grow at Significant Rate
7.4. UK Antibiotics Market
7.4.1. Increasing Investment for R&D for Antibiotic Resistance.
7.5. Germany Antibiotics Market
7.5.1. Increasing Use of Antibiotic in Ambulatory Care Unit.
7.6. France Antibiotics Market
7.6.1. Huge Consumption of Antibiotics and Has Highest Rate of Beta-Lactam Resistance in Streptococcus Pneumoniae.
7.7. Rest of Europe Antibiotics Market
8. Asia Pacific Antibiotics Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.2. Asia Pacific Antibiotics Market Size and Forecast by Type
8.2.1. Penicillin Submarket Expected to Grow at Significant Rate
8.3. Asia Pacific Antibiotics Market Size and Forecast by Mechanism
8.3.1. Cell Wall Synthesis Industry Submarket to Grow at Significant Rate
8.4. China Antibiotics Market
8.4.1. The Government Implementing Strategies to Control the Antimicrobial Resistance in Hospitals.
8.5. India Antibiotics Market
8.5.1. Increasing Consumption of Antibiotics for Human Use.
8.6. Japan Antibiotics Market
8.6.1. Increasing Antibiotic Prescription in The Region is Increasing.
8.7. Rest of Asia Pacific Antibiotics Market
9. Latin America Antibiotics Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.2. Latin America Antibiotics Market Size and Forecast by Type
9.2.1. Penicillin Submarket Expected to Grow at Significant Rate
9.3. Latin America Antibiotics Market Size and Forecast by Mechanism
9.3.1. Brazil Antibiotics Market
9.3.1.1. Increasing Antibiotic Sale in The Region.
9.3.2. Mexico Antibiotics Market
9.3.2.1. Adapting Strategies for Proper Antibiotic Use.
9.3.3. Rest of Latin America Antibiotics Market
9.3.3.1. Increasing Use of Antibiotics in Hospitals, Mostly for Surgical Prophylaxis and Nosocomial Infections.
10. MEA Antibiotics Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.2. MEA Antibiotics Market Size and Forecast by Type
10.2.1. Penicillin submarket Expected to Grow at Significant Rate
10.3. MEA Antibiotics Market Size and Forecast By Mechanism
10.4. South Africa Antibiotics Market
10.4.1.1. Increasing Antibiotic Prescription for Respiratory Tract & Common Infection.
10.5. Rest of MEA Antibiotics Market
10.5.1.1. Availability of Antibiotic in the Region.
11. Companies in the Antibiotics Market
11.1. Pfizer, Inc.
11.1.1. Company Snapshot
11.1.2. Company Overview
11.1.3. Financial Performance (2015-2020)
11.1.3.1. Net Revenue
11.1.4. Product Offerings
11.1.5. Recent Initiatives (2017-2020)
11.2. Thermo Fischer Scientific Inc
11.2.1. Company Snapshot
11.2.2. Company Overview
11.2.3. Financial Performance (2015-2020)
11.2.3.1. Net Revenue
11.2.3.2. Gross Profit
11.2.4. Product Offerings
11.2.5. Recent Initiatives (2017-2020)
11.3. Astellas Pharma, Inc
11.3.1. Company Snapshot
11.3.2. Company Overview
11.3.3. Financial Performance (2015-2020)
11.3.3.1. Net Revenue
11.3.3.2. Gross Profit
11.3.4. Product Offerings
11.3.5. Recent Initiatives (2017-2020)
11.4. F. Hoffmann-La Roche AG
11.4.1. Company Snapshot
11.4.2. Company Overview
11.4.3. Financial Performance (2015-2020)
11.4.3.1. Net Revenue
11.4.4. Product Offerings
11.4.5. Recent Initiatives (2017-2020)
11.5. Novartis AG
11.5.1. Company Snapshot
11.5.2. Company Overview
11.5.3. Financial Performance (2015-2020)
11.5.3.1. Net Revenue
11.5.4. Product Offerings
11.5.5. Recent Initiatives (2017-2020)
11.6. Bristol-Myers Squibb Co.
11.6.1. Company Snapshot
11.6.2. Company Overview
11.6.3. Financial Performance (2015-2020)
11.6.3.1. Net Revenue
11.6.3.2. Geographical Revenue, 2020
11.6.4. Product Offerings
11.6.5. Recent Initiatives (2017-2020)
11.7. Bayer HealthCare AG
11.7.1. Company Snapshot
11.7.2. Company Overview
11.7.3. Financial Performance (2015-2020)
11.7.3.1. Net Revenue
11.7.4. Product Offerings
11.7.5. Recent Initiatives (2017-2020)
11.8. Merck KGaA,
11.8.1. Company Snapshot
11.8.2. Company Overview
11.8.3. Financial Performance (2015-2020)
11.8.3.1. Net Revenue
11.8.3.2. Gross Profit
11.8.4. Product Offerings
11.8.5. Recent Initiatives (2017-2020)
11.9. Abbott Laboratories
11.9.1. Company Snapshot
11.9.2. Company Overview
11.9.3. Financial Performance (2015-2020)
11.9.3.1. Net Revenue
11.9.4. Product Offerings
11.9.5. Recent Initiatives (2017-2020)
11.10. Takeda Pharmaceutical Company Ltd.
11.10.1. Company Snapshot
11.10.2. Company Overview
11.10.3. Financial Performance (2015-2020)
11.10.3.1. Net Revenue
11.10.3.2. Gross Profit
11.10.4. Product Offerings
11.10.5. Recent Initiatives (2017-2020)
11.11. Other Notable Players
12. Conclusion
13. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1. Antibiotics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2. Antibiotics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3. Antibiotics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4. Antibiotics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5. Antibiotics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6. Antibiotics Market Drivers & Restraints 2021
Table 7. Antibiotics Submarket Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 8. Antibiotics Submarket Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 9. Antibiotics Submarket Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 10. Antibiotics Submarket Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 11. Antibiotics Submarket Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 12. Cephalosporins Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 13. Cephalosporins Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14. Cephalosporins Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15. Cephalosporins Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16. Cephalosporins Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17. Macrolides Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 18. Macrolides Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 19. Macrolides Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 20. Macrolides Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 21. Macrolides Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 22. Macrolides Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 23. Macrolides Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 24. Macrolides Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 25. Macrolides Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 26. Macrolides Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 27. Tetracycline Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 28. Tetracycline Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 29. Tetracycline Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 30. Tetracycline Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 31. Tetracycline Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 32. Penicillin Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 33. Penicillin Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 34. Penicillin Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 35. Penicillin Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 36. Penicillin Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 37. Fluoroquinolones Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 38. Fluoroquinolones Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 39. Aminoglycosides Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 40. Fluoroquinolones Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 41. Fluoroquinolones Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 42. Aminoglycosides Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 43. Aminoglycosides Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 44. Aminoglycosides Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 45. Aminoglycosides Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 46. Aminoglycosides Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 47. Antibiotics Market Forecast by Mechanism 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 48. Antibiotics Market Forecast by Mechanism 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 49. Antibiotics Market Forecast by Mechanism 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 50. Antibiotics Market Forecast by Mechanism 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 51. Antibiotics Market Forecast by Mechanism 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 52. Cell Wall Synthesis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 53. Cell Wall Synthesis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 54. Cell Wall Synthesis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 55. Cell Wall Synthesis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 56. Cell Wall Synthesis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 57. Protein Synthesis Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 58. Protein Synthesis Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 59. Protein Synthesis Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 60. Protein Synthesis Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 61. Protein Synthesis Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 62. DNA Synthesis Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table63. DNA Synthesis Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 64. DNA Synthesis Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 65. DNA Synthesis Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 66. DNA Synthesis Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 67. Mycolic Acid synthesis inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table68. Mycolic Acid synthesis inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 69. Mycolic Acid synthesis inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 70. Mycolic Acid synthesis inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 71. Mycolic Acid synthesis inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 72. Folic Acid synthesis inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table73. Folic Acid synthesis inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 74. Folic Acid synthesis inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table75. Folic Acid synthesis inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 76. Folic Acid synthesis inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 77. Regional Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 78. Regional Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 79. Regional Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 80. Regional Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 81. Regional Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 82. North America Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 83. North America Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 84. North America Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 85. North America Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 86. North America Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 87. North America Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 88. North America Antibiotics Market Forecast by Mechanism 2021-2031(US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 89. North America Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 90. North America Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table91. North America Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 92. North America Antibiotics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 93. North America Antibiotics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 94. North America Antibiotics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 95. North America Antibiotics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 96. North America Antibiotics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 97. US Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 98. US Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 99. US Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 100. US Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 101. US Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 102. Canada Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 103. Canada Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 104. Canada Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 105. Canada Antibiotics Market Forecast 2021-2031 (US$M, AGR %CAGR %) (COVID - Scenario W)
Table 106. Canada Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 107. Europe Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 108. Europe Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 109. Europe Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 110. Europe Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 111. Europe Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 112. Europe Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 113. Europe Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 114. Europe Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 115. Europe Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 116. Europe Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 117. Europe Antibiotics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 118. Europe Antibiotics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 119. Europe Antibiotics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 120. Europe Antibiotics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 121. Europe Antibiotics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 122. UK Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 123. UK Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 124. UK Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 125. UK Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 126. UK Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 127. Germany Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 128. Germany Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 129. Germany Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 130. Germany Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 131. Germany Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 132. France Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 133. France Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 134. France Antibiotics Market Forecast 2021-2031 (US$M, AGR %CAGR %) (COVID - Scenario U)
Table 135. France Antibiotics Market Forecast 2021-2031 (US$M, AGR %CAGR %), (COVID - Scenario W)
Table 136. France Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 137. Rest of Europe Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 138. Rest of Europe Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 139. Rest of Europe Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 140. Rest of Europe Antibiotics Market Forecast 2021-2031 (US$M, AGR%, CAGR %) (COVID - Scenario W)
Table 141. Rest of Europe Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 142. Asia Pacific Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 143. Asia Pacific Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 144. Asia Pacific Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 145. Asia Pacific Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 146. Asia Pacific Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 147. Asia Pacific Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 148. Asia Pacific Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 149. Asia Pacific Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 150. Asia Pacific Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 151. Asia Pacific Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L
Table 152. Asia Pacific Antibiotics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 153. Asia Pacific Antibiotics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 154. Asia Pacific Antibiotics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 155. Asia Pacific Antibiotics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 156. Asia Pacific Antibiotics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 157. China Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 158. China Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 159. China Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 160. China Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 161. China Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 162. India Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 163. India Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 164. India Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 165. India Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 166. India Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 167. Japan Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 168. Japan Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 169. Japan Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 170. Japan Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 171. Japan Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 172. RoAPAC Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 173. RoAPAC Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 174. RoAPAC Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 175. RoAPAC Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 176. RoAPAC Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 177. Middle East Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 178. Middle East Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 179. Middle East Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 180 Middle East Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 181. Middle East Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 182 Middle East Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 183 Middle East Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 184. Middle East Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 185 Middle East Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 186. Middle East Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 187. Latin America Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 188. Latin America Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 189. Latin America Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 190. Latin America Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W
Table 191. Latin America Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 192. Latin America Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 193. Latin America Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 194 Latin America Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 195. Latin America Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 196. Latin America Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 197 Leading 10 Antibiotics Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 198. Pfizer Inc. Profile 2020 (CEO, HQ, Founded, Website)
Table 199. Pfizer Inc. Antibiotics Selected Recent Contracts 2020 (Date, Programme Type, Details)
Table 200. Pfizer Inc. Antibiotics Product Offering (Segment, Product Offerings)
Table 201. Thermo Fischer Scientific Inc. Profile 2020 (CEO, HQ, Founded, Website)
Table 202. Thermo Fischer Scientific Inc. Antibiotics Product Offering (Segment, Product Offerings)
Table 203. Astellas Pharma, Inc. Profile 2020 (CEO, HQ, Founded, Website)
Table 204. Astellas Pharma, Inc Antibiotics Selected Recent Contracts 2017-2020 (Date, Programme Type, Details)
Table 205. Astellas Pharma, Inc Antibiotics Product Offering (Segment, Product Offerings)
Table 206. F. Hoffmann-La Roche AG Profile 2020 (CEO, HQ, Founded, Website)
Table 207. F. Hoffmann-La Roche AG Selected Recent Contracts 2015-2020 (Date, Programme Type, Details)
Table 208. F. Hoffmann-La Roche AG Antibiotics Product Offering (Segment, Product Offerings)
Table 209. Novartis AG Profile 2020 (CEO, HQ, Founded, Website)
Table 210. Novartis AG Antibiotics Product Offering (Segment, Product Offerings)
Table 211. Bristol-Myers Squibb Co. Profile 2020 (CEO, HQ, Founded, Website)
Table 212. Bristol-Myers Squibb Co. Antibiotics Selected Recent Contracts 2015-2020 (Date, Programme Type, Details)
Table 213 Bristol-Myers Squibb Co. Antibiotics Product Offering (Segment, Product Offerings)
Table 214. Bayer HealthCare AG Profile 2020 (CEO, HQ, Founded, Website)
Table 215. Bayer HealthCare AG Antibiotics Product Offering (Segment, Product Offerings)
Table 216. Merck KGaA, Profile 2020 (CEO, HQ, Founded, Website)
Table 217. Merck KGaA Antibiotics Product Offering (Segment, Product Offerings)
Table 218. Abbott Laboratories Profile 2020 (CEO, HQ, Founded, Website)
Table 219. Abbott Laboratories Antibiotics Product Offering (Segment, Product Offerings)
Table 220. Takeda Pharmaceutical Company Ltd. Profile 2020 (CEO, Total Company Sales US$M, HQ, Founded, No. of Employees, Ticker, Website)
Table 221. Takeda Pharmaceutical Company Ltd. Total Company Sales 2015-2020(US$M, AGR %)
Table 222. Takeda Pharmaceutical Company Ltd. Product Offering (Segment, Product Offerings)
Table 223. Other Companies Involved in the Antibiotics Market (Company, Location)
LIST OF FIGURES
Figure 1. Antibiotics Market Type Overview
Figure 2. Antibiotics Market by Type Overview
Figure 3. Antibiotics Market Mechanism Overview
Figure 4 Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 5. Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 6. Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 7. Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 8. Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 9. Antibiotics Submarket Forecast by Type 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 10. Antibiotics Submarket Forecast by Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 11. Antibiotics Submarket Forecast by Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 12. Antibiotics Submarket Forecast by Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 13. Antibiotics Submarket Forecast by Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 14. Penicillin Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 15. Penicillin Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID – Scenario V)
Figure 16. Penicillin Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario U)
Figure 17. Penicillin Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario W)
Figure 18. Penicillin Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario L)
Figure 19. Antibiotics Submarket Forecast by Mechanism 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 20. Antibiotics Submarket Forecast by Mechanism 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 21. Antibiotics Submarket Forecast by Mechanism 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 22. Antibiotics Submarket Forecast by Mechanism 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 23. Antibiotics Submarket Forecast by Mechanism 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 24. Food and Beverages Industry Submarket Forecast 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 25. Food and Beverages Industry Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario V)
Figure 26. Food and Beverages Industry Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario U)
Figure 27. Food and Beverages Industry Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario W)
Figure 28. Food and Beverages Industry Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario L)
Figure 29. Regional Antibiotics Market Forecast 2021-2031 (Sales US$M, Global AGR %)
Figure 30. Regional Antibiotics Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario V)
Figure 31. Regional Antibiotics Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario U)
Figure 32. Regional Antibiotics Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario W)
Figure 33. Regional Antibiotics Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario L)
Figure 34. North America Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %) (Before COVID)
Figure 35. North America Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 36. North America Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 37. North America Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 38. North America Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 39. North America Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %)
Figure 40. North America Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 41. North America Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 42. North America Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 43. North America Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 44. North America Antibiotics Market Forecast by Country 2021-2031 (US$M, AGR %) (Before COVID)
Figure 45. North America Antibiotics Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 46. North America Antibiotics Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 47. North America Antibiotics Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 48. North America Antibiotics Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 49. US Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 50. US Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 51. US Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 52. US Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 53. US Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 54. Canada Antibiotics Market Forecast 2021-2031 (US$M, AGR %)
Figure 55. Canada Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 56. Canada Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 57. Canada Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 58. Canada Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 59. Europe Antibiotics Market Forecast by Type 2021-2031 (US$M)
Figure 60. Europe Antibiotics Market Forecast by Type 2021-2031 (US$M) (COVID - Scenario V)
Figure 61. Europe Antibiotics Market Forecast by Type 2021-2031 (US$M) (COVID - Scenario U)
Figure 62. Europe Antibiotics Market Forecast by Type 2021-2031 (US$M) (COVID - Scenario W)
Figure 63. Europe Antibiotics Market Forecast by Type 2021-2031 (US$M) (COVID - Scenario L)
Figure 64. Europe Antibiotics Market Forecast by Mechanism 2021-2031 (US$M) (Before COVID)
Figure 65. Europe Antibiotics Market Forecast by Mechanism 2021-2031 (US$M) (COVID - Scenario V)
Figure 66. Europe Antibiotics Market Forecast by Mechanism 2021-2031 (US$M) (COVID - Scenario U)
Figure 67. Europe Antibiotics Market Forecast by Mechanism 2021-2031 (US$M) (COVID - Scenario W)
Figure 68. Europe Antibiotics Market Forecast by Mechanism 2021-2031 (US$M) (COVID - Scenario L)
Figure 69. Europe Antibiotics Market Forecast by Country 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 70. Europe Antibiotics Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 71. Europe Antibiotics Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 72. Europe Antibiotics Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 73. Europe Antibiotics Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 74. UK Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 75. UK Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 76. UK Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID – Scenario U)
Figure 77. UK Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 78. UK Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 79. Germany Antibiotics Market Forecast 2021-2031 (US$M, AGR %)
Figure 80. Germany Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 81. Germany Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 82. Germany Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 83. Germany Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 84. France Antibiotics Market Forecast 2021-2031 (US$M, AGR %)
Figure 85. France Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 86. France Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 87. France Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 88. France Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 89. Rest of Europe Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 90. Rest of Europe Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 91. Rest of Europe Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 92. Rest of Europe Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 93. Rest of Europe Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 94 Asia-Pacific Antibiotics Market Forecast by Type 2021-2031 (US$M) (Before COVID)
Figure 95. Asia-Pacific Antibiotics Market Forecast by Type 2021-2031 (US$M) (COVID - Scenario V)
Figure 96. Asia-Pacific Antibiotics Market Forecast by Type 2021-2031 (US$M) (COVID - Scenario U)
Figure 97. Asia-Pacific Antibiotics Market Forecast by Type 2021-2031 (US$M) (COVID - Scenario W)
Figure 98. Asia-Pacific Antibiotics Market Forecast by Type 2021-2031 (US$M) (COVID - Scenario L)
Figure 99. Asia-Pacific Antibiotics Market Forecast by Mechanism 2021-2031 (US$M) (COVID - Scenario V)
Figure 100. Asia-Pacific Antibiotics Market Forecast by Mechanism 2021-2031 (US$M) (COVID - Scenario U)
Figure 101. Asia-Pacific Antibiotics Market Forecast by Mechanism 2021-2031 (US$M) (COVID - Scenario W)
Figure 102. Asia-Pacific Antibiotics Market Forecast by Mechanism 2021-2031 (US$M) (COVID - Scenario L)
Figure 103. Asia-Pacific Antibiotics Market Forecast by Country 2021-2031 (US$M, AGR %) (Before COVID)
Figure 104. Asia-Pacific Antibiotics Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 105. Asia-Pacific Antibiotics Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 106. Asia-Pacific Antibiotics Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 107. Asia-Pacific Antibiotics Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 108. China Antibiotics Market Forecast 2021-2031 (US$M, AGR %)
Figure 109. China Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 110. China Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 111 China Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 112. China Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 113. India Antibiotics Market Forecast 2021-2031 (US$M, AGR %)
Figure 114. India Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 115. India Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 116. India Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 117. India Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 118. Japan Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 119. Japan Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 120. Japan Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 121. Japan Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 122. Japan Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 123. Rest of APAC Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 124. Rest of APAC Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 125 Rest of APAC Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 126. Rest of APAC Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 127. Rest of APAC Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 128. Middle East Antibiotics Market Forecast by Type 2021-2031 (US$M)
Figure 129. Middle East Antibiotics Market Forecast by Type 2021-2031 (US$M) (COVID - Scenario V)
Figure 130. Middle East Antibiotics Market Forecast by Type 2021-2031 (US$M) (COVID - Scenario U)
Figure 131. Middle East Antibiotics Market Forecast by Type 2021-2031 (US$M) (COVID - Scenario W)
Figure 132. Middle East Antibiotics Market Forecast by Type 2021-2031 (US$M) (COVID - Scenario L)
Figure 133. Middle East Antibiotics Market Forecast by Mechanism 2021-2031 (US$M)
Figure 134. Middle East Antibiotics Market Forecast by Mechanism 2021-2031 (US$M) (COVID - Scenario V)
Figure 135. Middle East Antibiotics Market Forecast by Mechanism 2021-2031 (US$M) (COVID - Scenario U)
Figure 136. Middle East Antibiotics Market Forecast by Mechanism 2021-2031 (US$M) (COVID - Scenario W)
Figure 137. Middle East Antibiotics Market Forecast by Mechanism 2021-2031 (US$M) (COVID - Scenario L)
Figure 138. Rest of Middle East Antibiotics Market Forecast 2021-2031 (US$M, AGR %)
Figure 139. Rest of Middle East Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 140. Rest of Middle East Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 141. Rest of Middle East Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 142. Rest of Middle East Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 143. Latin America Antibiotics Market Forecast by Type 2021-2031 (US$M)
Figure 144. Latin America Antibiotics Market Forecast by Type 2021-2031 (US$M) (COVID - Scenario V)
Figure 145. Latin America Antibiotics Market Forecast by Type 2021-2031 (US$M) (COVID - Scenario U)
Figure 146. Latin America Antibiotics Market Forecast by Type 2021-2031 (US$M) (COVID - Scenario W)
Figure 147. Latin America Antibiotics Market Forecast by Type 2021-2031 (US$M) (COVID - Scenario L)
Figure 148. Latin America Antibiotics Market Forecast by Mechanism 2021-2031 (US$M)
Figure 149. Latin America Antibiotics Market Forecast by Mechanism 2021-2031 (US$M) (COVID - Scenario V)
Figure 150. Latin America Antibiotics Market Forecast by Mechanism 2021-2031 (US$M) (COVID - Scenario U)
Figure 151. Latin America Antibiotics Market Forecast by Mechanism 2021-2031 (US$M) (COVID - Scenario W)
Figure 152. Latin America Antibiotics Market Forecast by Mechanism 2021-2031 (US$M) (COVID - Scenario L)
Figure 153. Rest of Latin America Antibiotics Market Forecast 2021-2031 (US$M, AGR %)
Figure 154. Rest of Latin America Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 155. Rest of Latin America Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 156. Rest of Latin America Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 157. Rest of Latin America Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 158. Porter’s Five Force Analysis
Companies Mentioned
1. Pfizer, Inc.
2. Thermo Fisher Scientific Inc.
3. Astellas Pharma, Inc
4. F. Hoffmann-La Roche AG
5. Novartis AG
6. Bristol-Myers Squibb Co.
7. Bayer HealthCare AG
8. Merck KGaA,
9. Abbott Laboratories
10. Takeda Pharmaceutical Company Ltd.
11. Daiichi Sankyo Company, Ltd.
12. GlaxoSmithKline Plc
13. Eli Lilly and Co.
14. Kyorin Pharmaceutical Co., Ltd.
15. Janssen Pharmaceuticals
16. Sanofi S.A.
17. Creative Biolabs., Inc.
18. Paratek Pharmaceuticals, Inc.
19. Novo- Nordisk
20. Boehringer Ingelheim
21. Becton, Dickinson and Company
22. Shionogi & Co., Ltd.
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered by This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Antibiotics Market
2.1. Antibiotics Market Definition
2.2. By Type Submarkets Definitions
2.3. By Mechanism Submarkets Definitions
3. Antibiotics Market Overview
3.1. Global Antibiotics Market Size and Forecast by Region
3.2. Global Antibiotics Market Share by Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Development in Clinical Trials
3.3.1.2. Rising Demand for Antibiotics to Treat Children with Potentially Fatal Sepsis and Pneumonia.
3.3.1.3. Increasing Prevalence of Infectious Diseases
3.3.1.4. Growing Disposable Income
3.3.2. Market Restraints/Challenges
3.3.2.1. Antibiotic Resistance is Major Threat.
3.3.2.2. Development of Antibiotic That are Active Against Antibiotic Resistance.
3.3.3. Opportunities
3.3.3.1. Rising Investment in R&D.
3.3.3.2. Increasing Use of Antibiotics in Veterinary to Prevent Diseases.
3.3.3.3. Growing Need to Prevent Infection in Surgical Patients, Cancer Patients and Patients with Compromised Immune Systems.
3.3.4. Porter’s Five Forces Analysis
3.3.4.1. Competitive Rivalry
3.3.4.2. Supplier Power
3.3.4.3. Buyer Power
3.3.4.4. Threat of Substitution
3.3.4.5. Threat of New Entry
4. Global Antibiotics Market Analysis and Forecast 2021-2031, By Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.2. Cephalosporins
4.2.1.1. Used to Treat Serious Infections, Such as Septicaemia and Meningitis
4.3. Macrolides
4.3.1.1. Used to Treat Penicillin-Resistant Strains of Bacteria.
4.4. Tetracycline
4.4.1.1. Commonly Treat Moderate to Severe Acne and Rosacea.
4.5. Penicillin
4.5.1.1. Broadly Used to Treat Infections, Such as Skin, Ear, Respiratory and Dental Infections.
4.6. Fluoroquinolones
4.6.1.1. Increasing use of Ciprofloxacin, Levofloxacin, to Treat Pneumonia, Sinus, Joint, Urinary Infections, among others.
4.7. Aminoglycosides
4.7.1.1. Used in Hospital to Treat Serious Infections Such as Septicaemia.
5. Global Antibiotics Market Analysis and Forecast, 2021-2031 by Mechanism (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Cell Wall Synthesis
5.1.1.1. Penicillin and Cephalosporins are Major Antibiotics That Inhibit Bacterial Cell Wall Synthesis.
5.1.2. Protein Synthesis Inhibitors
5.1.2.1. Act at the Ribosome Level.
5.1.3. DNA Synthesis Inhibitors
5.1.3.1. Fluoroquinolone Blocks DNA Replication Via Inhibition of DNA Gyrase
5.1.4. RNA Synthesis Inhibitors
5.1.4.1. Rifampin is Effective Against Intracellular Phagocytized Staphylococcus Aureus in Macrophages
5.1.5. Mycolic Acid Synthesis Inhibitors
5.1.5.1. Isoniazid, Mycolic Acid Synthesis Inhibitor.
5.1.6. Folic Acid Synthesis Inhibitors
5.1.6.1. Sulfonamides and Trimethoprim Sequential Blockage of Folic Acid Synthesis.
6. North America Antibiotics Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.2. North America Antibiotics Market Size and Forecast by Type
6.2.1. Penicillin Submarket Expected to Grow at Significant Rate
6.3. North America Antibiotics Market Size and Forecast by Mechanism
6.3.1. Cell Wall Synthesis Industry Submarket to Grow at Significant Rate
6.4. U.S. Antibiotics Market
6.4.1. World Antimicrobial Awareness Week (WAAW) Focuses to Increase Awareness of Antibiotic Resistance
6.5. Canada Antibiotics Market
6.5.1. Increasing Antibiotic Prescription for Respiratory and Urinary Tract Infections (UTI).
7. Europe Antibiotics Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.2. Europe Antibiotics Market Size and Forecast by Type
7.2.1. Penicillin Submarket Expected to Grow at Significant Rate
7.3. Europe Antibiotics Market Size and Forecast by Mechanism
7.3.1. Cell Wall Synthesis Submarket to Grow at Significant Rate
7.4. UK Antibiotics Market
7.4.1. Increasing Investment for R&D for Antibiotic Resistance.
7.5. Germany Antibiotics Market
7.5.1. Increasing Use of Antibiotic in Ambulatory Care Unit.
7.6. France Antibiotics Market
7.6.1. Huge Consumption of Antibiotics and Has Highest Rate of Beta-Lactam Resistance in Streptococcus Pneumoniae.
7.7. Rest of Europe Antibiotics Market
8. Asia Pacific Antibiotics Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.2. Asia Pacific Antibiotics Market Size and Forecast by Type
8.2.1. Penicillin Submarket Expected to Grow at Significant Rate
8.3. Asia Pacific Antibiotics Market Size and Forecast by Mechanism
8.3.1. Cell Wall Synthesis Industry Submarket to Grow at Significant Rate
8.4. China Antibiotics Market
8.4.1. The Government Implementing Strategies to Control the Antimicrobial Resistance in Hospitals.
8.5. India Antibiotics Market
8.5.1. Increasing Consumption of Antibiotics for Human Use.
8.6. Japan Antibiotics Market
8.6.1. Increasing Antibiotic Prescription in The Region is Increasing.
8.7. Rest of Asia Pacific Antibiotics Market
9. Latin America Antibiotics Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.2. Latin America Antibiotics Market Size and Forecast by Type
9.2.1. Penicillin Submarket Expected to Grow at Significant Rate
9.3. Latin America Antibiotics Market Size and Forecast by Mechanism
9.3.1. Brazil Antibiotics Market
9.3.1.1. Increasing Antibiotic Sale in The Region.
9.3.2. Mexico Antibiotics Market
9.3.2.1. Adapting Strategies for Proper Antibiotic Use.
9.3.3. Rest of Latin America Antibiotics Market
9.3.3.1. Increasing Use of Antibiotics in Hospitals, Mostly for Surgical Prophylaxis and Nosocomial Infections.
10. MEA Antibiotics Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.2. MEA Antibiotics Market Size and Forecast by Type
10.2.1. Penicillin submarket Expected to Grow at Significant Rate
10.3. MEA Antibiotics Market Size and Forecast By Mechanism
10.4. South Africa Antibiotics Market
10.4.1.1. Increasing Antibiotic Prescription for Respiratory Tract & Common Infection.
10.5. Rest of MEA Antibiotics Market
10.5.1.1. Availability of Antibiotic in the Region.
11. Companies in the Antibiotics Market
11.1. Pfizer, Inc.
11.1.1. Company Snapshot
11.1.2. Company Overview
11.1.3. Financial Performance (2015-2020)
11.1.3.1. Net Revenue
11.1.4. Product Offerings
11.1.5. Recent Initiatives (2017-2020)
11.2. Thermo Fischer Scientific Inc
11.2.1. Company Snapshot
11.2.2. Company Overview
11.2.3. Financial Performance (2015-2020)
11.2.3.1. Net Revenue
11.2.3.2. Gross Profit
11.2.4. Product Offerings
11.2.5. Recent Initiatives (2017-2020)
11.3. Astellas Pharma, Inc
11.3.1. Company Snapshot
11.3.2. Company Overview
11.3.3. Financial Performance (2015-2020)
11.3.3.1. Net Revenue
11.3.3.2. Gross Profit
11.3.4. Product Offerings
11.3.5. Recent Initiatives (2017-2020)
11.4. F. Hoffmann-La Roche AG
11.4.1. Company Snapshot
11.4.2. Company Overview
11.4.3. Financial Performance (2015-2020)
11.4.3.1. Net Revenue
11.4.4. Product Offerings
11.4.5. Recent Initiatives (2017-2020)
11.5. Novartis AG
11.5.1. Company Snapshot
11.5.2. Company Overview
11.5.3. Financial Performance (2015-2020)
11.5.3.1. Net Revenue
11.5.4. Product Offerings
11.5.5. Recent Initiatives (2017-2020)
11.6. Bristol-Myers Squibb Co.
11.6.1. Company Snapshot
11.6.2. Company Overview
11.6.3. Financial Performance (2015-2020)
11.6.3.1. Net Revenue
11.6.3.2. Geographical Revenue, 2020
11.6.4. Product Offerings
11.6.5. Recent Initiatives (2017-2020)
11.7. Bayer HealthCare AG
11.7.1. Company Snapshot
11.7.2. Company Overview
11.7.3. Financial Performance (2015-2020)
11.7.3.1. Net Revenue
11.7.4. Product Offerings
11.7.5. Recent Initiatives (2017-2020)
11.8. Merck KGaA,
11.8.1. Company Snapshot
11.8.2. Company Overview
11.8.3. Financial Performance (2015-2020)
11.8.3.1. Net Revenue
11.8.3.2. Gross Profit
11.8.4. Product Offerings
11.8.5. Recent Initiatives (2017-2020)
11.9. Abbott Laboratories
11.9.1. Company Snapshot
11.9.2. Company Overview
11.9.3. Financial Performance (2015-2020)
11.9.3.1. Net Revenue
11.9.4. Product Offerings
11.9.5. Recent Initiatives (2017-2020)
11.10. Takeda Pharmaceutical Company Ltd.
11.10.1. Company Snapshot
11.10.2. Company Overview
11.10.3. Financial Performance (2015-2020)
11.10.3.1. Net Revenue
11.10.3.2. Gross Profit
11.10.4. Product Offerings
11.10.5. Recent Initiatives (2017-2020)
11.11. Other Notable Players
12. Conclusion
13. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1. Antibiotics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2. Antibiotics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3. Antibiotics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4. Antibiotics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5. Antibiotics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6. Antibiotics Market Drivers & Restraints 2021
Table 7. Antibiotics Submarket Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 8. Antibiotics Submarket Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 9. Antibiotics Submarket Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 10. Antibiotics Submarket Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 11. Antibiotics Submarket Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 12. Cephalosporins Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 13. Cephalosporins Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14. Cephalosporins Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15. Cephalosporins Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16. Cephalosporins Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17. Macrolides Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 18. Macrolides Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 19. Macrolides Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 20. Macrolides Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 21. Macrolides Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 22. Macrolides Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 23. Macrolides Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 24. Macrolides Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 25. Macrolides Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 26. Macrolides Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 27. Tetracycline Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 28. Tetracycline Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 29. Tetracycline Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 30. Tetracycline Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 31. Tetracycline Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 32. Penicillin Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 33. Penicillin Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 34. Penicillin Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 35. Penicillin Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 36. Penicillin Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 37. Fluoroquinolones Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 38. Fluoroquinolones Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 39. Aminoglycosides Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 40. Fluoroquinolones Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 41. Fluoroquinolones Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 42. Aminoglycosides Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 43. Aminoglycosides Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 44. Aminoglycosides Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 45. Aminoglycosides Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 46. Aminoglycosides Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 47. Antibiotics Market Forecast by Mechanism 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 48. Antibiotics Market Forecast by Mechanism 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 49. Antibiotics Market Forecast by Mechanism 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 50. Antibiotics Market Forecast by Mechanism 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 51. Antibiotics Market Forecast by Mechanism 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 52. Cell Wall Synthesis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 53. Cell Wall Synthesis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 54. Cell Wall Synthesis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 55. Cell Wall Synthesis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 56. Cell Wall Synthesis Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 57. Protein Synthesis Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 58. Protein Synthesis Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 59. Protein Synthesis Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 60. Protein Synthesis Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 61. Protein Synthesis Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 62. DNA Synthesis Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table63. DNA Synthesis Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 64. DNA Synthesis Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 65. DNA Synthesis Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 66. DNA Synthesis Inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 67. Mycolic Acid synthesis inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table68. Mycolic Acid synthesis inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 69. Mycolic Acid synthesis inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 70. Mycolic Acid synthesis inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 71. Mycolic Acid synthesis inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 72. Folic Acid synthesis inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table73. Folic Acid synthesis inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 74. Folic Acid synthesis inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table75. Folic Acid synthesis inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 76. Folic Acid synthesis inhibitors Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 77. Regional Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 78. Regional Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 79. Regional Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 80. Regional Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 81. Regional Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 82. North America Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 83. North America Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 84. North America Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 85. North America Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 86. North America Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 87. North America Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 88. North America Antibiotics Market Forecast by Mechanism 2021-2031(US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 89. North America Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 90. North America Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table91. North America Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 92. North America Antibiotics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 93. North America Antibiotics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 94. North America Antibiotics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 95. North America Antibiotics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 96. North America Antibiotics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 97. US Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 98. US Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 99. US Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 100. US Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 101. US Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 102. Canada Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 103. Canada Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 104. Canada Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 105. Canada Antibiotics Market Forecast 2021-2031 (US$M, AGR %CAGR %) (COVID - Scenario W)
Table 106. Canada Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 107. Europe Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 108. Europe Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 109. Europe Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 110. Europe Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 111. Europe Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 112. Europe Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 113. Europe Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 114. Europe Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 115. Europe Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 116. Europe Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 117. Europe Antibiotics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 118. Europe Antibiotics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 119. Europe Antibiotics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 120. Europe Antibiotics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 121. Europe Antibiotics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 122. UK Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 123. UK Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 124. UK Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 125. UK Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 126. UK Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 127. Germany Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 128. Germany Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 129. Germany Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 130. Germany Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 131. Germany Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 132. France Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 133. France Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 134. France Antibiotics Market Forecast 2021-2031 (US$M, AGR %CAGR %) (COVID - Scenario U)
Table 135. France Antibiotics Market Forecast 2021-2031 (US$M, AGR %CAGR %), (COVID - Scenario W)
Table 136. France Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 137. Rest of Europe Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 138. Rest of Europe Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 139. Rest of Europe Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 140. Rest of Europe Antibiotics Market Forecast 2021-2031 (US$M, AGR%, CAGR %) (COVID - Scenario W)
Table 141. Rest of Europe Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 142. Asia Pacific Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 143. Asia Pacific Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 144. Asia Pacific Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 145. Asia Pacific Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 146. Asia Pacific Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 147. Asia Pacific Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 148. Asia Pacific Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 149. Asia Pacific Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 150. Asia Pacific Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 151. Asia Pacific Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L
Table 152. Asia Pacific Antibiotics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 153. Asia Pacific Antibiotics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 154. Asia Pacific Antibiotics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 155. Asia Pacific Antibiotics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 156. Asia Pacific Antibiotics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 157. China Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 158. China Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 159. China Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 160. China Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 161. China Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 162. India Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 163. India Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 164. India Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 165. India Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 166. India Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 167. Japan Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 168. Japan Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 169. Japan Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 170. Japan Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 171. Japan Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 172. RoAPAC Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 173. RoAPAC Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 174. RoAPAC Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 175. RoAPAC Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 176. RoAPAC Antibiotics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 177. Middle East Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 178. Middle East Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 179. Middle East Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 180 Middle East Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 181. Middle East Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 182 Middle East Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 183 Middle East Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 184. Middle East Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 185 Middle East Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 186. Middle East Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 187. Latin America Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 188. Latin America Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 189. Latin America Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 190. Latin America Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W
Table 191. Latin America Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 192. Latin America Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 193. Latin America Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 194 Latin America Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 195. Latin America Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 196. Latin America Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 197 Leading 10 Antibiotics Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 198. Pfizer Inc. Profile 2020 (CEO, HQ, Founded, Website)
Table 199. Pfizer Inc. Antibiotics Selected Recent Contracts 2020 (Date, Programme Type, Details)
Table 200. Pfizer Inc. Antibiotics Product Offering (Segment, Product Offerings)
Table 201. Thermo Fischer Scientific Inc. Profile 2020 (CEO, HQ, Founded, Website)
Table 202. Thermo Fischer Scientific Inc. Antibiotics Product Offering (Segment, Product Offerings)
Table 203. Astellas Pharma, Inc. Profile 2020 (CEO, HQ, Founded, Website)
Table 204. Astellas Pharma, Inc Antibiotics Selected Recent Contracts 2017-2020 (Date, Programme Type, Details)
Table 205. Astellas Pharma, Inc Antibiotics Product Offering (Segment, Product Offerings)
Table 206. F. Hoffmann-La Roche AG Profile 2020 (CEO, HQ, Founded, Website)
Table 207. F. Hoffmann-La Roche AG Selected Recent Contracts 2015-2020 (Date, Programme Type, Details)
Table 208. F. Hoffmann-La Roche AG Antibiotics Product Offering (Segment, Product Offerings)
Table 209. Novartis AG Profile 2020 (CEO, HQ, Founded, Website)
Table 210. Novartis AG Antibiotics Product Offering (Segment, Product Offerings)
Table 211. Bristol-Myers Squibb Co. Profile 2020 (CEO, HQ, Founded, Website)
Table 212. Bristol-Myers Squibb Co. Antibiotics Selected Recent Contracts 2015-2020 (Date, Programme Type, Details)
Table 213 Bristol-Myers Squibb Co. Antibiotics Product Offering (Segment, Product Offerings)
Table 214. Bayer HealthCare AG Profile 2020 (CEO, HQ, Founded, Website)
Table 215. Bayer HealthCare AG Antibiotics Product Offering (Segment, Product Offerings)
Table 216. Merck KGaA, Profile 2020 (CEO, HQ, Founded, Website)
Table 217. Merck KGaA Antibiotics Product Offering (Segment, Product Offerings)
Table 218. Abbott Laboratories Profile 2020 (CEO, HQ, Founded, Website)
Table 219. Abbott Laboratories Antibiotics Product Offering (Segment, Product Offerings)
Table 220. Takeda Pharmaceutical Company Ltd. Profile 2020 (CEO, Total Company Sales US$M, HQ, Founded, No. of Employees, Ticker, Website)
Table 221. Takeda Pharmaceutical Company Ltd. Total Company Sales 2015-2020(US$M, AGR %)
Table 222. Takeda Pharmaceutical Company Ltd. Product Offering (Segment, Product Offerings)
Table 223. Other Companies Involved in the Antibiotics Market (Company, Location)
LIST OF FIGURES
Figure 1. Antibiotics Market Type Overview
Figure 2. Antibiotics Market by Type Overview
Figure 3. Antibiotics Market Mechanism Overview
Figure 4 Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 5. Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 6. Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 7. Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 8. Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 9. Antibiotics Submarket Forecast by Type 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 10. Antibiotics Submarket Forecast by Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 11. Antibiotics Submarket Forecast by Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 12. Antibiotics Submarket Forecast by Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 13. Antibiotics Submarket Forecast by Type 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 14. Penicillin Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 15. Penicillin Submarket Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID – Scenario V)
Figure 16. Penicillin Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario U)
Figure 17. Penicillin Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario W)
Figure 18. Penicillin Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario L)
Figure 19. Antibiotics Submarket Forecast by Mechanism 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 20. Antibiotics Submarket Forecast by Mechanism 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 21. Antibiotics Submarket Forecast by Mechanism 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 22. Antibiotics Submarket Forecast by Mechanism 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 23. Antibiotics Submarket Forecast by Mechanism 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 24. Food and Beverages Industry Submarket Forecast 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 25. Food and Beverages Industry Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario V)
Figure 26. Food and Beverages Industry Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario U)
Figure 27. Food and Beverages Industry Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario W)
Figure 28. Food and Beverages Industry Submarket Forecast 2021-2031 (US$M, Global AGR %) (COVID – Scenario L)
Figure 29. Regional Antibiotics Market Forecast 2021-2031 (Sales US$M, Global AGR %)
Figure 30. Regional Antibiotics Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario V)
Figure 31. Regional Antibiotics Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario U)
Figure 32. Regional Antibiotics Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario W)
Figure 33. Regional Antibiotics Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario L)
Figure 34. North America Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %) (Before COVID)
Figure 35. North America Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 36. North America Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 37. North America Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 38. North America Antibiotics Market Forecast by Type 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 39. North America Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %)
Figure 40. North America Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 41. North America Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 42. North America Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 43. North America Antibiotics Market Forecast by Mechanism 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 44. North America Antibiotics Market Forecast by Country 2021-2031 (US$M, AGR %) (Before COVID)
Figure 45. North America Antibiotics Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 46. North America Antibiotics Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 47. North America Antibiotics Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 48. North America Antibiotics Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 49. US Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 50. US Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 51. US Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 52. US Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 53. US Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 54. Canada Antibiotics Market Forecast 2021-2031 (US$M, AGR %)
Figure 55. Canada Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 56. Canada Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 57. Canada Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 58. Canada Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 59. Europe Antibiotics Market Forecast by Type 2021-2031 (US$M)
Figure 60. Europe Antibiotics Market Forecast by Type 2021-2031 (US$M) (COVID - Scenario V)
Figure 61. Europe Antibiotics Market Forecast by Type 2021-2031 (US$M) (COVID - Scenario U)
Figure 62. Europe Antibiotics Market Forecast by Type 2021-2031 (US$M) (COVID - Scenario W)
Figure 63. Europe Antibiotics Market Forecast by Type 2021-2031 (US$M) (COVID - Scenario L)
Figure 64. Europe Antibiotics Market Forecast by Mechanism 2021-2031 (US$M) (Before COVID)
Figure 65. Europe Antibiotics Market Forecast by Mechanism 2021-2031 (US$M) (COVID - Scenario V)
Figure 66. Europe Antibiotics Market Forecast by Mechanism 2021-2031 (US$M) (COVID - Scenario U)
Figure 67. Europe Antibiotics Market Forecast by Mechanism 2021-2031 (US$M) (COVID - Scenario W)
Figure 68. Europe Antibiotics Market Forecast by Mechanism 2021-2031 (US$M) (COVID - Scenario L)
Figure 69. Europe Antibiotics Market Forecast by Country 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 70. Europe Antibiotics Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 71. Europe Antibiotics Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 72. Europe Antibiotics Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 73. Europe Antibiotics Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 74. UK Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 75. UK Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 76. UK Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID – Scenario U)
Figure 77. UK Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 78. UK Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 79. Germany Antibiotics Market Forecast 2021-2031 (US$M, AGR %)
Figure 80. Germany Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 81. Germany Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 82. Germany Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 83. Germany Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 84. France Antibiotics Market Forecast 2021-2031 (US$M, AGR %)
Figure 85. France Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 86. France Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 87. France Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 88. France Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 89. Rest of Europe Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 90. Rest of Europe Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 91. Rest of Europe Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 92. Rest of Europe Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 93. Rest of Europe Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 94 Asia-Pacific Antibiotics Market Forecast by Type 2021-2031 (US$M) (Before COVID)
Figure 95. Asia-Pacific Antibiotics Market Forecast by Type 2021-2031 (US$M) (COVID - Scenario V)
Figure 96. Asia-Pacific Antibiotics Market Forecast by Type 2021-2031 (US$M) (COVID - Scenario U)
Figure 97. Asia-Pacific Antibiotics Market Forecast by Type 2021-2031 (US$M) (COVID - Scenario W)
Figure 98. Asia-Pacific Antibiotics Market Forecast by Type 2021-2031 (US$M) (COVID - Scenario L)
Figure 99. Asia-Pacific Antibiotics Market Forecast by Mechanism 2021-2031 (US$M) (COVID - Scenario V)
Figure 100. Asia-Pacific Antibiotics Market Forecast by Mechanism 2021-2031 (US$M) (COVID - Scenario U)
Figure 101. Asia-Pacific Antibiotics Market Forecast by Mechanism 2021-2031 (US$M) (COVID - Scenario W)
Figure 102. Asia-Pacific Antibiotics Market Forecast by Mechanism 2021-2031 (US$M) (COVID - Scenario L)
Figure 103. Asia-Pacific Antibiotics Market Forecast by Country 2021-2031 (US$M, AGR %) (Before COVID)
Figure 104. Asia-Pacific Antibiotics Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 105. Asia-Pacific Antibiotics Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 106. Asia-Pacific Antibiotics Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 107. Asia-Pacific Antibiotics Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 108. China Antibiotics Market Forecast 2021-2031 (US$M, AGR %)
Figure 109. China Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 110. China Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 111 China Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 112. China Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 113. India Antibiotics Market Forecast 2021-2031 (US$M, AGR %)
Figure 114. India Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 115. India Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 116. India Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 117. India Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 118. Japan Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 119. Japan Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 120. Japan Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 121. Japan Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 122. Japan Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 123. Rest of APAC Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 124. Rest of APAC Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 125 Rest of APAC Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 126. Rest of APAC Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 127. Rest of APAC Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 128. Middle East Antibiotics Market Forecast by Type 2021-2031 (US$M)
Figure 129. Middle East Antibiotics Market Forecast by Type 2021-2031 (US$M) (COVID - Scenario V)
Figure 130. Middle East Antibiotics Market Forecast by Type 2021-2031 (US$M) (COVID - Scenario U)
Figure 131. Middle East Antibiotics Market Forecast by Type 2021-2031 (US$M) (COVID - Scenario W)
Figure 132. Middle East Antibiotics Market Forecast by Type 2021-2031 (US$M) (COVID - Scenario L)
Figure 133. Middle East Antibiotics Market Forecast by Mechanism 2021-2031 (US$M)
Figure 134. Middle East Antibiotics Market Forecast by Mechanism 2021-2031 (US$M) (COVID - Scenario V)
Figure 135. Middle East Antibiotics Market Forecast by Mechanism 2021-2031 (US$M) (COVID - Scenario U)
Figure 136. Middle East Antibiotics Market Forecast by Mechanism 2021-2031 (US$M) (COVID - Scenario W)
Figure 137. Middle East Antibiotics Market Forecast by Mechanism 2021-2031 (US$M) (COVID - Scenario L)
Figure 138. Rest of Middle East Antibiotics Market Forecast 2021-2031 (US$M, AGR %)
Figure 139. Rest of Middle East Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 140. Rest of Middle East Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 141. Rest of Middle East Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 142. Rest of Middle East Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 143. Latin America Antibiotics Market Forecast by Type 2021-2031 (US$M)
Figure 144. Latin America Antibiotics Market Forecast by Type 2021-2031 (US$M) (COVID - Scenario V)
Figure 145. Latin America Antibiotics Market Forecast by Type 2021-2031 (US$M) (COVID - Scenario U)
Figure 146. Latin America Antibiotics Market Forecast by Type 2021-2031 (US$M) (COVID - Scenario W)
Figure 147. Latin America Antibiotics Market Forecast by Type 2021-2031 (US$M) (COVID - Scenario L)
Figure 148. Latin America Antibiotics Market Forecast by Mechanism 2021-2031 (US$M)
Figure 149. Latin America Antibiotics Market Forecast by Mechanism 2021-2031 (US$M) (COVID - Scenario V)
Figure 150. Latin America Antibiotics Market Forecast by Mechanism 2021-2031 (US$M) (COVID - Scenario U)
Figure 151. Latin America Antibiotics Market Forecast by Mechanism 2021-2031 (US$M) (COVID - Scenario W)
Figure 152. Latin America Antibiotics Market Forecast by Mechanism 2021-2031 (US$M) (COVID - Scenario L)
Figure 153. Rest of Latin America Antibiotics Market Forecast 2021-2031 (US$M, AGR %)
Figure 154. Rest of Latin America Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 155. Rest of Latin America Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 156. Rest of Latin America Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 157. Rest of Latin America Antibiotics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 158. Porter’s Five Force Analysis
Companies Mentioned
1. Pfizer, Inc.
2. Thermo Fisher Scientific Inc.
3. Astellas Pharma, Inc
4. F. Hoffmann-La Roche AG
5. Novartis AG
6. Bristol-Myers Squibb Co.
7. Bayer HealthCare AG
8. Merck KGaA,
9. Abbott Laboratories
10. Takeda Pharmaceutical Company Ltd.
11. Daiichi Sankyo Company, Ltd.
12. GlaxoSmithKline Plc
13. Eli Lilly and Co.
14. Kyorin Pharmaceutical Co., Ltd.
15. Janssen Pharmaceuticals
16. Sanofi S.A.
17. Creative Biolabs., Inc.
18. Paratek Pharmaceuticals, Inc.
19. Novo- Nordisk
20. Boehringer Ingelheim
21. Becton, Dickinson and Company
22. Shionogi & Co., Ltd.
Companies Profiled in the Report
1. Pfizer, Inc.
2. Thermo Fisher Scientific Inc.
3. Astellas Pharma, Inc
4. F. Hoffmann-La Roche AG
5. Novartis AG
6. Bristol-Myers Squibb Co.
7. Bayer HealthCare AG
8. Merck KGaA,
9. Abbott Laboratories
10. Takeda Pharmaceutical Company Ltd.
11. Daiichi Sankyo Company, Ltd.
12. GlaxoSmithKline Plc
13. Eli Lilly and Co.
14. Kyorin Pharmaceutical Co., Ltd.
List of Companies Mentioned in the Report:
1. Pfizer Inc.
2. Thermo Fisher Scientific Inc.
3. Astellas Pharma, Inc
4. F. Hoffmann-La Roche AG
5. Novartis AG
6. Bristol-Myers Squibb Co.
7. Bayer HealthCare AG
8. Merck KGaA,
9. Abbott Laboratories
10. Takeda Pharmaceutical Company Ltd.
11. Daiichi Sankyo Company, Ltd.
12. GlaxoSmithKline Plc
13. Eli Lilly and Co.
14. Kyorin Pharmaceutical Co., Ltd.
15. Janssen Pharmaceuticals
16. Sanofi S.A.
17. Creative Biolabs., Inc.
18. Paratek Pharmaceuticals, Inc.
19. Novo- Nordisk
20. Boehringer Ingelheim
21. Becton, Dickinson and Company
22. Shionogi & Co., Ltd.
List of Organizations Mentioned in the Report
1. World Health Organization
2. European Rapid Alert System for Food and Feed (RASFF)
3. US Food & Drug Administration
4. US National Library of Medicine
5. National Institutes of Health
6. National Association for Biomedical Research
7. Center for Disease Control and Prevention CDC
8. National Foundation for Infectious Diseases.
9. The Pew Foundation’s Antibiotic Resistance Project’s
10. Hazard Analysis Critical Control Point (HACCP)
11. The Reportable Food Registry (RFR)
12. Clinical Infectious Diseases
13. Government of Canada
14. The European Free Trade Association Surveillance Authority (ESA)
15. Center for Diseases Dynamics, Economics & Policy (CDDEP)
16. National Reference Laboratory of Veterinary Drug Residues
17. The Federation of Veterinarians of Europe
18. Microbiology Society
19. Gastrointestinal Society
20. The Global Health Security Agenda (GHSA)
1. Pfizer, Inc.
2. Thermo Fisher Scientific Inc.
3. Astellas Pharma, Inc
4. F. Hoffmann-La Roche AG
5. Novartis AG
6. Bristol-Myers Squibb Co.
7. Bayer HealthCare AG
8. Merck KGaA,
9. Abbott Laboratories
10. Takeda Pharmaceutical Company Ltd.
11. Daiichi Sankyo Company, Ltd.
12. GlaxoSmithKline Plc
13. Eli Lilly and Co.
14. Kyorin Pharmaceutical Co., Ltd.
List of Companies Mentioned in the Report:
1. Pfizer Inc.
2. Thermo Fisher Scientific Inc.
3. Astellas Pharma, Inc
4. F. Hoffmann-La Roche AG
5. Novartis AG
6. Bristol-Myers Squibb Co.
7. Bayer HealthCare AG
8. Merck KGaA,
9. Abbott Laboratories
10. Takeda Pharmaceutical Company Ltd.
11. Daiichi Sankyo Company, Ltd.
12. GlaxoSmithKline Plc
13. Eli Lilly and Co.
14. Kyorin Pharmaceutical Co., Ltd.
15. Janssen Pharmaceuticals
16. Sanofi S.A.
17. Creative Biolabs., Inc.
18. Paratek Pharmaceuticals, Inc.
19. Novo- Nordisk
20. Boehringer Ingelheim
21. Becton, Dickinson and Company
22. Shionogi & Co., Ltd.
List of Organizations Mentioned in the Report
1. World Health Organization
2. European Rapid Alert System for Food and Feed (RASFF)
3. US Food & Drug Administration
4. US National Library of Medicine
5. National Institutes of Health
6. National Association for Biomedical Research
7. Center for Disease Control and Prevention CDC
8. National Foundation for Infectious Diseases.
9. The Pew Foundation’s Antibiotic Resistance Project’s
10. Hazard Analysis Critical Control Point (HACCP)
11. The Reportable Food Registry (RFR)
12. Clinical Infectious Diseases
13. Government of Canada
14. The European Free Trade Association Surveillance Authority (ESA)
15. Center for Diseases Dynamics, Economics & Policy (CDDEP)
16. National Reference Laboratory of Veterinary Drug Residues
17. The Federation of Veterinarians of Europe
18. Microbiology Society
19. Gastrointestinal Society
20. The Global Health Security Agenda (GHSA)
Download sample pages
Complete the form below to download your free sample pages for Antibiotics Market Report to 2031Download sample pages
Complete the form below to download your free sample pages for Antibiotics Market Report to 2031Do you have any custom requirements we can help you with?
Any specific country, geo region, market segment or specific company information?
Email us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
Would you like a free report overview of the report of your choice?
If so, please drop an email to Sara Peerun stating your chosen report title to sara.peerun@visiongain.com
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
Would you like to get the latest Visiongain pharma reports catalogue?
What are the dynamic growth sectors? where are the regional business opportunities?
Which technologies will prevail and who are the leading companies succeeding in these sectors and why?
If you want definitive answers to business critical questions, discover Visiongain’s full range of business intelligence reports.
If so, please email Sara Peerun on sara.peerun@visiongain.com or call her today on +44 (0) 20 7549 9987
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia
Win a Free Visiongain Pharma report – ‘Like’ our Pharma Facebook page with the link below and enter into our raffle to win a free, unlocked Visiongain report, choosing your relevant report from our reports selection.Click here to ‘Like’ our Facebook page https://www.facebook.com/V.G.Pharma/
Visiongain Pharma
Visiongain Pharma
Visiongain PharmaLatest Pharma news
Visiongain Publishes Dermatological Drugs Market Report 2021-2031
The global market for dermatological drugs is ascending and has made significant gains in skin treatments. The players in the dermatological drugs market are striving to tap the opportunities that this market offers.
18 January 2021
Visiongain Publishes Antigen Skin Test Market Report to 2031
The study covers detailed and insightful chapters on market overview, market segments, new developments, competitive landscape, strategic recommendations, key company analysis, market opportunities, pricing analysis, gap analysis, porter’s 5 forces model, company profiling, geographical analysis, and analytical overview of the market. Increasing health concerns among population and growing incidences of fungal & bacterial infection are some of the factors driving the growth of Antigen Skin Test market.
12 January 2021
Visiongain Publishes Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Report 2021
Fierce competition, stringent regulations, diminishing research and development, shrinking margins, strong price pressures and patent cliffs encompass today’s drug industry. It is a well-known fact that future of the pharmaceutical/biopharmaceutical industry depends on innovation, and innovation comes from collaborations or partnerships.
11 January 2021
Visiongain Publishes Anti-Infective Vaccines Market Report Report to 2031
The study covers detailed and insightful chapters on market overview, market segments, new developments, competitive landscape, strategic recommendations, key company analysis, market opportunities, pricing analysis, gap analysis, porter’s 5 forces model, company profiling, geographical analysis, and analytical overview of the market.
11 January 2021
